STING1 and acute myeloid leukemia: Further insight into the unique mechanisms of immune evasion in AML is needed, but early data suggest promising immunotherapeutic approaches with TLR agonists, the calreticulin-CD47 pathway, STING activation, and STAT3 inhibition.